Melane Sampson, Author at BioTuesdays

Executive Moves

Three key appointments strengthen Amphista’s clinical development capabilities

Closely held Amphista Therapeutics has announced the appointments of Dr. Lisa Butler as SVP of clinical operations, Dr. Alexandra Sevko as VP of translational science, and Nicola Lindsay as head of project and portfolio...

October 23, 2025

Developments

Three peer-reviewed studies reveal Nexalin’s DIFS potential in AD

Nexalin Technology (NASDAQ: NXL) has announced that three independently published, peer-reviewed clinical studies collectively demonstrate the ability of its proprietary 15 mA Gen-2 Nexalin DIFS technology to improve...

October 21, 2025

Developments

Tenon receives FDA 510(k) clearance for joint fusion system

Tenon Medical (NASDAQ:TNON) has announced that the FDA has granted 510(k) clearance for its SImmetry+ SI Joint Fusion System indicated for sacroiliac (SI) joint fusion for conditions including sacroiliac joint...

October 21, 2025

Feature

In conversation with Dr. Tyler Evans, co-founder, CEO and CMO of Wellness Equity Alliance

Tyler B. Evans, MD, MS, MPH, is a leading voice in global health equity, infectious disease, and humanitarian medicine. As co-founder, CEO, and chief medical officer of Wellness Equity Alliance (WEA), Dr. Evans has...

October 21, 2025

Developments

USPTO publishes patent application for Clearmind’s MEAI for binge behavior disorders

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the publication of a patent application by the USPTO for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as...

October 20, 2025

Developments

Profound congratulates Busch Center for 500th TULSA procedure achieved

Profound Medical (NASDAQ: PROF; TSX: PRN) has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and...

October 16, 2025

Developments

Theravance launches education campaign for nOH associated with MSA

Theravance Biopharma (NASDAQ: TBPH) has announced the launch of Power in the Periphery—a new disease education campaign to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic...

October 16, 2025

Developments

First patient dosed in Adicet’s trial of ADI-001 in RA

Adicet Bio (NASDAQ: ACET) has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory rheumatoid arthritis (RA). The company’s Phase 1 study is designed...

October 16, 2025

Executive Moves

Dr. Bali Pulendran joins Candel’s research advisory board

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of internationally recognized expert in systems immunology and vaccinology, Bali Pulendran, PhD, to Candel’s research advisory board. Dr. Pulendran is the...

October 16, 2025

Executive Moves

James Rawls, PharmD, joins LB as SVP of regulatory affairs

LB Pharmaceuticals (NASDAQ: LBRX) has announced the appointment of James Rawls, PharmD, as senior vice president (SVP) of regulatory affairs. With more than 25 years of regulatory leadership experience across global...

October 14, 2025

Author - Melane Sampson

Three key appointments strengthen Amphista’s clinical development capabilities

Three peer-reviewed studies reveal Nexalin’s DIFS potential in AD

Tenon receives FDA 510(k) clearance for joint fusion system

In conversation with Dr. Tyler Evans, co-founder, CEO and CMO of Wellness Equity Alliance

USPTO publishes patent application for Clearmind’s MEAI for binge behavior disorders

Profound congratulates Busch Center for 500th TULSA procedure achieved

Theravance launches education campaign for nOH associated with MSA

First patient dosed in Adicet’s trial of ADI-001 in RA

Dr. Bali Pulendran joins Candel’s research advisory board

James Rawls, PharmD, joins LB as SVP of regulatory affairs

Subscribe